Drug Safety Stays At Top Of FDA’s Agenda With New Guidances In The Works
Executive Summary
Drug safety will remain a primary focus of FDA's guidance development efforts, according to the Center for Drug Evaluation & Research's 2006 guidance agenda
You may also be interested in...
Liver Toxicity Guidance Urges Sponsors To Include Risky Patients In Trials
FDA's recent draft guidance on drug-induced liver injury recommends drug developers enroll patients with preexisting liver disease in at least Phase III clinical trials, especially if the drug might eventually be used in such patients.
Liver Toxicity Guidance Urges Sponsors To Include Risky Patients In Trials
FDA's recent draft guidance on drug-induced liver injury recommends drug developers enroll patients with preexisting liver disease in at least Phase III clinical trials, especially if the drug might eventually be used in such patients.
FDA’s Guidance Agenda Includes Risk Communication, Pain, Diabetes
FDA is preparing to issue further guidance on appropriate communication of risk information over the next year, according to CDER's 2007 guidance agenda